Title:  Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a
systematic review and meta-analysis
Version: 1 Date: 09 Oct 2023
Reviewer:  Tsunehiko Maruyama
Reviewer's report:
As the author has mentioned in his limitations, information on RAS and BRAF is considered
essential. In addition, the site of the primary tumor is also necessary information.
The comparison of BEV to placebo and BEV to CET and PAN makes the results unclear.
Title:  Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a
systematic review and meta-analysis
Version: 1 Date: 09 Oct 2023
Reviewer:  Tsunehiko Maruyama
Reviewer's report:
As the author has mentioned in his limitations, information on RAS and BRAF is considered
essential. In addition, the site of the primary tumor is also necessary information.
The comparison of BEV to placebo and BEV to CET and PAN makes the results unclear.
Please review this paper.
user
Title:  Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a
systematic review and meta-analysis
Version: 1 Date: 09 Oct 2023
Reviewer:  Tsunehiko Maruyama
Reviewer's report:
As the author has mentioned in his limitations, information on RAS and BRAF is considered
essential. In addition, the site of the primary tumor is also necessary information.
The comparison of BEV to placebo and BEV to CET and PAN makes the results unclear.
assistant